Gyre Therapeutics

Quarterly Financials

Values in thousands2025-12-312025-09-302025-06-302025-03-31
Revenue
$37,195
$30,564
$26,771
$22,058
Gross Profit
35,452
28,936
25,620
21,164
EBITDA
815
8,278
2,813
2,808
EBIT
120
7,629
2,172
2,273
Net Income
-1,723
3,610
442
2,698
Net Change In Cash
37,195
30,564
26,771
22,058
Free Cash Flow
-5,769
3,993
1,809
-950
Cash
37,070
40,402
36,491
15,045
Basic Shares
911,561
102,701
102,701
101,970

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$116,588
$105,757
$113,450
$102,290
Gross Profit
111,172
101,873
108,814
97,497
EBITDA
14,011
17,817
20,327
10,332
EBIT
11,491
16,229
19,213
9,203
Net Income
5,027
12,085
-92,933
2,302
Net Change In Cash
116,588
105,757
113,450
102,290
Free Cash Flow
-180
-6,769
17,306
5,679
Cash
37,070
11,813
33,509
25,175
Basic Shares
103,180
102,293
65,831
75,686

Earnings Calls

QuarterEPS
2026-03-31
$0
2025-12-31
$0.04
2025-09-30
$0.03
2025-06-30
$0.002